PROVE2: Phase II study of VX950 (telaprevir) in combination with peginterferon alfa2a with or without ribavirin in subjects with chronic hepatitis C, first interim analysis

被引：0
|
作者：
Hezode, Christophe
Ferenci, Peter
Dusheiko, Geoffrey M.
Pol, Stanislas
Goeser, Tobias
Bronowicki, Jean-Pierre
Gharakhanian, Shahin
Devonish, Desiree
Kauffman, Robert
Alam, John
Pawlotsky, Jean-Michel
Zeuzem, Stefan
机构：
[1] Hop Henri Mondor, AP HP, Hepatogastroenterol Serv, F-94010 Creteil, France
[2] Med Univ Vienna, Vienna, Austria
[3] Royal Free Hosp, Ctr Hepatol, London NW3 2QG, England
[4] Necker Cochin Hosp, AP HP, Liver Unit, Paris, France
[5] Univ Cologne, Cologne, Germany
[6] Nancy Univ Hosp Ctr, CHU, Nancy, France
[7] Vertex Pharmaceut Inc, Med Dev Grp, Cambridge, MA USA
[8] Hop Henri Mondor, AP HP, Dept Bacterol & Virol, F-94010 Creteil, France
[9] Saarland Univ Hosp, Internal Med Clin 2, Homburg, Germany
来源：
HEPATOLOGY | 2007年 / 46卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
80
引用
收藏
页码：268A / 269A
页数：2
相关论文
共 50 条
  • [41] COX-2 inhibitor enhances the efficacy of peginterferon-alfa 2a and ribavirin combination therapy for chronic hepatitis C
    Kagawa, Tatehiro
    Arose, Yoshitaka
    Hirose, Shunji
    Kojima, Sei-ichiro
    Nagata, Naruhiko
    Shiraishi, Koichi
    Mine, Tetsuya
    HEPATOLOGY, 2012, 56 : 998A - 998A
  • [42] VX-222/TELAPREVIR IN COMBINATION WITH PEGINTERFERON-ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 1 HCV PATIENTS TREATED FOR 12 WEEKS: ZENITH STUDY, SVR12 INTERIM ANALYSIS
    Nelson, David R.
    Gane, Edward J.
    Jacobson, Ira M.
    Di Bisceglie, Adrian M.
    Alves, Katia
    Koziel, Margaret J.
    De Souza, Cynthia
    Kieffer, Tara L.
    George, Shelley
    Rosario, Maria
    Kauffman, Robert S.
    Sulkowski, Mark S.
    HEPATOLOGY, 2011, 54 : 1435A - 1435A
  • [43] Phase 2 study of the combination of merimepodib with peginterferon-α2b, and ribavirin in nonresponders to previous therapy for chronic hepatitis C
    Marcellin, Patrick
    Horsmans, Yves
    Nevens, Frederik
    Grange, Jean-Didier
    Bronowicki, Jean-Pierre
    Vetter, Denis
    Purdy, Susan
    Garg, Varun
    Bengtsson, Leif
    McNair, Lindsay
    Alam, John
    JOURNAL OF HEPATOLOGY, 2007, 47 (04) : 476 - 483
  • [44] Twice Daily Telaprevir in Combination with Peginterferon Alfa-2a/Ribavirin in HCV Genotype 1 Liver Transplant Recipients: Interim Safety/Efficacy of the REFRESH Study
    Brown, R.
    Russo, M.
    Levitsky, J.
    Brown, K.
    Fontana, R.
    Vargas, H.
    Yoshida, E.
    Bsharat, M.
    Rubin, R.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 145 - 145
  • [45] Ketoprofen,peginterferon 2a and ribavirin for genotype 1 chronic hepatitis C:A phaseⅡ study
    Annagiulia Gramenzi
    Carmela Cursaro
    Marzia Margotti
    Clara Balsano
    Alessandra Spaziani
    Simona Anticoli
    Elisabetta Loggi
    Maddalena Salerno
    Silvia Galli
    Giuliano Furlini
    Mauro Bernardi
    Pietro Andreone
    World Journal of Gastroenterology, 2009, 15 (47) : 5946 - 5952
  • [46] Twice Daily Telaprevir in Combination with Peginterferon Alfa-2a/Ribavirin in HCV Genotype 1 Liver Transplant Recipients: Interim Pharmacokinetics of the REFRESH Study.
    Vargas, H.
    Dai, Y.
    Brown, K.
    Russo, M.
    Yoshida, E.
    Fontana, R.
    Levitsky, J.
    Rubin, R.
    Garg, V.
    Brown, R.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 347 - 347
  • [47] Tolerability and antiviral effects in a 28-day study of the hepatitis C protease inhibitor Telaprevir (VX-950), in combination with peg-interforon-alpha-2a and ribavirin
    Lawitz, E.
    Rodriguez-Torres, M.
    Muir, A.
    Keane, J.
    Kieffer, T.
    McNair, L.
    McHutchison, J.
    JOURNAL OF CLINICAL VIROLOGY, 2006, 36 : S239 - S239
  • [48] Effect of combination therapy peginterferon alfa-2b and ribavirin on prevention of hepatocellular carcinoma in advanced chronic hepatitis C
    Honda, Takashi
    Katano, Yoshiaki
    Kuzuya, Teiji
    Hayashi, Kazuhiko
    Ishigami, Masatoshi
    Nakano, Isao
    Toyoda, Hidenori
    Kumada, Takashi
    Yoshioka, Kentaro
    Goto, Hidemi
    HEPATOLOGY, 2012, 56 : 1002A - 1003A
  • [49] Cost-effectiveness of peginterferon alfa-2b in combination with ribavirin as initial treatment for chronic hepatitis C in Sweden
    Bernfort, Lars
    Sennfalt, Karin
    Reichard, Olle
    SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2006, 38 (6-7) : 497 - 505
  • [50] A randomized controlled clinical study of lower-dose peginterferon alfa-2b in combination with ribavirin in the treatment of chronic hepatitis C
    罗端德
    ChinaMedicalAbstracts(InternalMedicine), 2006, (04) : 196 - 196
12345